Literature DB >> 25352883

Isolation and purification of psoralen and isopsoralen and their efficacy and safety in the treatment of osteosarcoma in nude rats.

Honghui Lu1, Lihai Zhang1, Daohong Liu1, Peifu Tang1, Feixiang Song1.   

Abstract

BACKGROUND: Modern studies have shown that psoralen has a significant inhibitory effect on tumor growth in a variety of animals and humans.
OBJECTIVE: To obtain coumarin compounds - psoralen and isopsoralen - from traditional Chinese medicine Psoralea corylifolia L. using chromatographic techniques and isolation and purification methods, and to observe the transplanted tumor growth inhibitory effects and adverse reactions of psoralen and isopsoralen in nude rats with osteosarcoma.
METHODS: Dried ripe fruits of Psoralea corylifolia L. were taken as the raw material to prepare crude extract of Psoralea corylifolia L. by ethanol reflux method. Column chromatography was used to isolate the crude extract; compounds were structurally identified based on (1)H-NMR, (13)C-NMR spectra, the two compounds were identified as psoralen andisopsoralen, and their contents were 99.7% and 99.6, respectively. Nude rat model of osteosarcoma was established; the rats were randomized into: normal saline group, psoralen low- and high-dose groups, isopsoralen low- and high-dose groups, and cisplatin group. Osteosarcoma volume and weight inhibition rates in nude rats in each group were observed; radioimmunoassay was used to determine the serum alkaline phosphatase activity; peripheral blood cell and bone marrow nucleated cell counts were determined; light microscopy was used to observe heart, liver, spleen, lung, kidney, and tumor histopathology; and electron microscopy was used to observe the fine structure of tumor cells.
RESULTS: Tumor volume inhibition rates were 43.75% and 40.18%, respectively, in the psoralen and isopsoralen low-dose groups, and tumor weight inhibition rates were 38.83% and 37.77%. Tumor volume inhibition rates were 67.86% and 66.96%, respectively, in the psoralen and isopsoralen high-dose groups, and tumor weight inhibition rates were 49.47% and 47.87%. Psoralen and ispsoralen markedly lowered serum AKP level. Psoralen and isopsoralen induced apoptosis or necrosis of osteosarcoma. After administration of high doses of psoralen and isopsoralen, toxic reactions such as writhing, lassitude, and hypoactivity were seen. Kidney histopathology showed tubulointerstitial dilatation and congestion, and inflammatory cell aggregation in the renal intercellular space. Psoralen and isopsoralen did not cause any significant toxic side effects to the bone marrow, or other organs such as heart, lung, liver, and spleen.
CONCLUSION: Psoralen and isopsoralen have growth inhibitory effects on transplanted tumor in nude rats with osteosarcoma, and can induce tumor cell apoptosis or necrosis, without significant toxic effects.

Entities:  

Keywords:  Psoralea corylifolia L.; isopsoralen; osteosarcoma; psoralen

Mesh:

Substances:

Year:  2014        PMID: 25352883      PMCID: PMC4209630          DOI: 10.4314/ahs.v14i3.20

Source DB:  PubMed          Journal:  Afr Health Sci        ISSN: 1680-6905            Impact factor:   0.927


  6 in total

1.  Adjuvant and neoadjuvant chemotherapy for osteosarcoma of the extremities: 27 year experience at Rizzoli Institute, Italy.

Authors:  Gaetano Bacci; Alessandra Longhi; Franca Fagioli; Antonio Briccoli; Michela Versari; Piero Picci
Journal:  Eur J Cancer       Date:  2005-11-17       Impact factor: 9.162

2.  The expression of the urokinase plasminogen activator system in metastatic murine osteosarcoma: an in vivo mouse model.

Authors:  J L Fisher; P S Mackie; M L Howard; H Zhou; P F Choong
Journal:  Clin Cancer Res       Date:  2001-06       Impact factor: 12.531

3.  Pre- and post-chemotherapy alkaline phosphatase levels as prognostic indicators in adults with localised osteosarcoma.

Authors:  Jos A M Bramer; Adesegun A Abudu; Roger M Tillman; Simon R Carter; Vaiyapuri P Sumathi; Robert J Grimer
Journal:  Eur J Cancer       Date:  2005-11-07       Impact factor: 9.162

4.  Prognostic significance of serum alkaline phosphatase in osteosarcoma of the extremity treated with neoadjuvant chemotherapy: recent experience at Rizzoli Institute.

Authors:  Gaetano Bacci; Alessandra Longhi; Stefano Ferrari; Stefano Lari; Marco Manfrini; Davide Donati; Cristiana Forni; Michela Versari
Journal:  Oncol Rep       Date:  2002 Jan-Feb       Impact factor: 3.906

5.  Ganciclovir prodrug therapy is effective in a murine xenotransplant model of human lung cancer.

Authors:  Roland Kurdow; Arnd S Boehle; Sieglinde Haye; Lars Boenicke; Bodo Schniewind; Peter Dohrmann; Holger Kalthoff
Journal:  Ann Thorac Surg       Date:  2002-03       Impact factor: 4.330

6.  Psoralen photoactivation promotes morphological and functional changes in fibroblasts in vitro reminiscent of cellular senescence.

Authors:  G Herrmann; P Brenneisen; M Wlaschek; J Wenk; K Faisst; G Quel; C Hommel; G Goerz; T Ruzicka; T Krieg; H Sies; K Scharffetter-Kochanek
Journal:  J Cell Sci       Date:  1998-03       Impact factor: 5.285

  6 in total
  8 in total

1.  Ebola and other issues in the health sector in Africa.

Authors:  J K Tumwine
Journal:  Afr Health Sci       Date:  2014-09       Impact factor: 0.927

2.  Isopsoralen ameliorates H2O2-induced damage in osteoblasts via activating the Wnt/β-catenin pathway.

Authors:  Yu-Peng Li; Bin Wu; Jie Liang; Fei Li
Journal:  Exp Ther Med       Date:  2019-07-05       Impact factor: 2.447

Review 3.  Insights into the Action Mechanisms of Traditional Chinese Medicine in Osteoarthritis.

Authors:  Linfu Li; Haiqing Liu; Weimei Shi; Hai Liu; Jianqiong Yang; Daohua Xu; Hao Huang; Longhuo Wu
Journal:  Evid Based Complement Alternat Med       Date:  2017-01-22       Impact factor: 2.629

4.  Psoralen Inhibited Apoptosis of Osteoporotic Osteoblasts by Modulating IRE1-ASK1-JNK Pathway.

Authors:  Shuqing Chen; Yongqian Wang; Yubin Yang; Ting Xiang; Jiahui Liu; Houming Zhou; Xinlin Wu
Journal:  Biomed Res Int       Date:  2017-03-02       Impact factor: 3.411

5.  Isopsoralen-mediated suppression of bone marrow adiposity and attenuation of the adipogenic commitment of bone marrow-derived mesenchymal stem cells.

Authors:  Jian Wang; Sheng-Fa Li; Ting Wang; Chun-Han Sun; Liang Wang; Min-Jun Huang; Jian Chen; Shao-Wei Zheng; Nan Wang; Ying-Jun Zhang; Tian-Yu Chen
Journal:  Int J Mol Med       Date:  2017-02-06       Impact factor: 4.101

6.  Psoralen promotes the expression of cyclin D1 in chondrocytes via the Wnt/β-catenin signaling pathway.

Authors:  Wenwei Zheng; Pingdong Lin; Yuhuan Ma; Xiang Shao; Houhuang Chen; Da Chen; Xianxiang Liu; Xihai Li; Hongzhi Ye
Journal:  Int J Mol Med       Date:  2017-09-21       Impact factor: 4.101

7.  Isopsoralen Enhanced Osteogenesis by Targeting AhR/ERα.

Authors:  Luna Ge; Yazhou Cui; Kai Cheng; Jinxiang Han
Journal:  Molecules       Date:  2018-10-11       Impact factor: 4.411

8.  Psoralen-loaded lipid-polymer hybrid nanoparticles enhance doxorubicin efficacy in multidrug-resistant HepG2 cells.

Authors:  Yueling Yuan; Tiange Cai; Richard Callaghan; Qianwen Li; Yinghong Huang; Bingyue Wang; Qingqing Huang; Manling Du; Qianqian Ma; Peter Chiba; Yu Cai
Journal:  Int J Nanomedicine       Date:  2019-03-27
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.